-+ 0.00%
-+ 0.00%
-+ 0.00%

PMV Pharma Q1 FY26 net loss widens to $18.04 million

PUBT·05/12/2026 12:02:45
Listen to the news
PMV Pharma Q1 FY26 net loss widens to $18.04 million
  • PMV Pharmaceuticals posted a net loss of USD 18.04 million, widening from USD 17.44 million a year earlier.
  • Operating loss narrowed to USD 19.02 million as total operating expenses fell to USD 19.02 million, led by a 12.1% drop in R&D spending to USD 15.33 million.
  • Interest income, net slid to USD 980,000 from USD 1.94 million on lower interest rates and smaller interest-bearing balances.
  • Cash, cash equivalents, and marketable securities totaled USD 93.55 million at March 31, 2026; cash operating expenditures were USD 19.68 million in the quarter.
  • FDA granted rezatapopt orphan drug designation in March 2026 for TP53 Y220C-positive ovarian, fallopian tube, and primary peritoneal cancers; NDA submission for platinum-resistant/refractory ovarian cancer targeted for Q1 2027, with funding expected to last through end of Q2 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMV Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-218227), on May 12, 2026, and is solely responsible for the information contained therein.